SEC Form 4 · accession 0001209191-19-003996
ANAPTYSBIO, INC · ANAB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marco Londei
Officer — Chief Medical Officer
Period of report
Jan 15, 2019
Accepted (ET)
Jan 16, 2019 · 7:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001370053
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 26, 2018 | G | 122,500 | $0.00 | D | 22,377 | D | |
| Common Stock | Jan 15, 2019 | M | 19,075 | $6.93 | A | 41,452 | D | |
| Common StockF3 | Jan 15, 2019 | S | 4,181 | $69.2864 | D | 37,271 | D | |
| Common StockF4 | Jan 15, 2019 | S | 14,894 | $70.0413 | D | 22,377 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F6,F5 | $6.93 | Jan 15, 2019 | M | 19,075 | D | — | Aug 13, 2025 | Common Stock | 19,075 | 51,148 | D |
Explanation of responses
- F1Represents the number of shares of Issuer's common stock that were donated as a charitable contribution. The reporting person does not exercise voting or dispositive powers, directly or indirectly, over the donated shares following this transfer.
- F2The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F3The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.63 to $69.60 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.63 to $70.37 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
- F6In addition to the remaining options to purchase 51,148 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 148,060 shares of common stock, which options vest according to their terms, and (ii) 22,377 shares of common stock held directly.